Daniel A Schneider1, Timothy J Akhurst, Samuel Y Ngan, Satish K Warrier, Michael Michael, Andrew C Lynch, Luc Te Marvelde, Alexander G Heriot. 1. 1 Department of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia 2 Centre for Molecular Imaging, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia 3 Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia 4 Department of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia 5 Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Abstract
BACKGROUND: Management of rectal cancer has become multidisciplinary and is driven by the stage of the disease, with increased focus on restaging rectal cancer after neoadjuvant therapy. OBJECTIVE: The purpose of this study was to assess the relative impact of restaging after preoperative chemoradiation with FDG-PET scan, CT, and MRI in the management of patients with rectal cancer. DESIGN: This was a retrospective study from a single institution. SETTINGS: This study was conducted at a tertiary cancer center. PATIENTS: A total of 199 patients met the inclusion criteria: patients with rectal adenocarcinoma; staged with positron emission tomography, CT, and MRI; T2 to T4, N0 to N2, M0 to M1; treated with neoadjuvant chemoradiation 50.4 Gy and infusional 5-fluorouracil; and restaged 4 weeks after chemoradiation before surgery between 2003 and 2013. MAIN OUTCOME MEASURES: Comparisons of the tumor stage among different imaging modalities before and after neoadjuvant chemoradiation were performed. The impact of restaging on the management plan was assessed. RESULTS: The stage at presentation was T2, 8.04%; T3, 65.33%; T4, 26.63%; N0, 17.09%; N1, 47.74%; N2, 34.67%; M0, 81.91%; and M1, 18.09%. Changes in disease stage postneoadjuvant chemoradiation were observed in 99 patients (50%). The management plans of 29 patients (15%) were changed. The impact of each restaging modality on management for all of the patients was positron emission tomography, 11%; CT, 4%; and MRI, 4%. In patients with metastatic disease at primary staging, the relative impact of each restaging modality in changing management was positron emission tomography, 32%; CT, 18%; and MRI, 6%. LIMITATIONS: This study was limited by its single-center and retrospective design. Operations were performed 4 weeks after restaging. CONCLUSIONS: Changes in the extent of disease after long-course chemoradiotherapy result in changes of management in a significant percentage of patients. Positron emission tomography has the most significant impact in the change of management overall, and its use in restaging advanced rectal cancer should be further explored.
BACKGROUND: Management of rectal cancer has become multidisciplinary and is driven by the stage of the disease, with increased focus on restaging rectal cancer after neoadjuvant therapy. OBJECTIVE: The purpose of this study was to assess the relative impact of restaging after preoperative chemoradiation with FDG-PET scan, CT, and MRI in the management of patients with rectal cancer. DESIGN: This was a retrospective study from a single institution. SETTINGS: This study was conducted at a tertiary cancer center. PATIENTS: A total of 199 patients met the inclusion criteria: patients with rectal adenocarcinoma; staged with positron emission tomography, CT, and MRI; T2 to T4, N0 to N2, M0 to M1; treated with neoadjuvant chemoradiation 50.4 Gy and infusional 5-fluorouracil; and restaged 4 weeks after chemoradiation before surgery between 2003 and 2013. MAIN OUTCOME MEASURES: Comparisons of the tumor stage among different imaging modalities before and after neoadjuvant chemoradiation were performed. The impact of restaging on the management plan was assessed. RESULTS: The stage at presentation was T2, 8.04%; T3, 65.33%; T4, 26.63%; N0, 17.09%; N1, 47.74%; N2, 34.67%; M0, 81.91%; and M1, 18.09%. Changes in disease stage postneoadjuvant chemoradiation were observed in 99 patients (50%). The management plans of 29 patients (15%) were changed. The impact of each restaging modality on management for all of the patients was positron emission tomography, 11%; CT, 4%; and MRI, 4%. In patients with metastatic disease at primary staging, the relative impact of each restaging modality in changing management was positron emission tomography, 32%; CT, 18%; and MRI, 6%. LIMITATIONS: This study was limited by its single-center and retrospective design. Operations were performed 4 weeks after restaging. CONCLUSIONS: Changes in the extent of disease after long-course chemoradiotherapy result in changes of management in a significant percentage of patients. Positron emission tomography has the most significant impact in the change of management overall, and its use in restaging advanced rectal cancer should be further explored.
Authors: Lisa A Min; Francesca Castagnoli; Wouter V Vogel; Jisk P Vellenga; Joost J M van Griethuysen; Max J Lahaye; Monique Maas; Regina G H Beets Tan; Doenja M J Lambregts Journal: Br J Radiol Date: 2021-08-13 Impact factor: 3.629